Shiga toxin-producing Escherichia coli (STEC) represents a public health threat that can lead to serious problems, such as bloody diarrhea and hemolytic uremic syndrome in children in up to 10%-15% of ...

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the phase III RASolute 302 study of its ...

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbvie, Astrazeneca ...

Edgewise Therapeutics Inc. is pulling in $1.55 billion up front by selling its muscular dystrophy business, including its fast skeletal myosin inhibitor, sevasemten (EDG-5506), to Servier SA. The deal ...

The much-awaited phase III readout from Oculis Holding AG’s OCS-01 in diabetic macular edema (DME) fell short of expectations, delaying the possibility of a topical eye drop option for DME patients ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abiomed, Cercare, Cumberland, Edap, Getinge, Idb, Nestle, Regeneron, Samsung Bioepis, Sciclone, Siemens.

With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease ...

As generic versions of its blockbuster drug Ofev (nintedanib) start to hit the market, Boehringer Ingelheim GmbH looks to ...

Biomunex Pharmaceuticals SAS has entered into strategic collaborations with two AI-specialized companies – Gordion Bioscience ...

Apogee Therapeutics Inc. loaded up on what could total as much as $1.3 billion in financial fuel from Blackstone Life ...

Currently available treatments for chronic hepatitis D virus (HDV) infection rarely result in a cure after a defined treatment period. Researchers from Aligos Therapeutics Inc. hypothesized that ...

Anti-PD-1/PD-L1 therapy has shown success in the treatment of liver cancer and may reverse immune tolerance in chronic hepatitis B (CHB). Aligos Therapeutics Inc. has presented preclinical data on the ...